Anxiety;Ansiedade

Revista Brasileira de Medicina

Volumn 59, Issue 9, 2002, Pages 621-634

  Bernik, Márdo ^a   Corregiari, Fábio ^a  

^a NONE   (Brazil)

Author keywords

Anxiety; Psychiatric disorders; Social phobia

Indexed keywords

ATENOLOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ANXIETY DISORDER; DISEASE CLASSIFICATION; DOSE RESPONSE; HUMAN; NEUROBIOLOGY; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIMARY MEDICAL CARE; PROGNOSIS; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; REVIEW; SOCIAL PHOBIA; SYMPTOMATOLOGY;

EID: 0036756859     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. a Ed - (DSM-IV). American Psichiatric Association Press, Washington 1994.
2. Andrade, L Walters, EE; Gentil, V; Laurenti, R. Prevalence of ICD-10 mental disorders in a catchment area in the city of São Paulo, Brazil. Soc Psychiatry Psychiatr Epidemiol. 2002 Jul; 37(7):316-25.
3. a Ed. Edusp, São Paulo, 1997.
4. Bakker A, an Balkom AJ, van Dyck, R. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int Clin Psychopharmacol, 2000 Aug; 15 Suppl 2:S25-30.
5. Ballenge, JC; Burrows, GD; DuPont, RL et al. Alprazolam in panic disorder and agoraphobia: Results of a multicenter trial, I: Efficacy in short term treatment. Arch Gen Psychiatry 1988; 45:413-22.
6. Baldwin, D; Bobes, J; Stein, DJ, et al. Paroxetine in social phobia/social anxiety disorder: randomised, double-blind, placebo controlled study. Br J Psychiatry 1999; 175:120-6.
7. Ball, SG; Otto, MW, Pollack MH, et al: Predicting prospective episodes of depression in patients with panic disorder: A longitudinal study. J Consult Clin Psychol 934; 62:359-65.
8. Badow, DH; Vermilyea J, Blanchard EB, et al: The phenomenon of panic. J Abnorm Psychol 1985; 94:320-8
9. Bremner, JD, Krystal, JH; Southwick, SM, et al. Noradrer eigic mechanisms in stress na anxiety, I: Preclinical studies. Synapse 1996a; 23:28-38.
10. Bremner, JD, Krystal, JH; Southwick, SM, et al. Noradrenergic mechanisms in stress na anxiety, II: Clinical studies. Synapse 1996b; 23:39-51.
11. Clomipramine Collaborative Study Group: Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48:730-8.
12. Davidson, JRT, Hughes, DL, George, LK, et al. The epidemiology of social phobia: Findings from de Duke Epidemiological Catchment Area Study. Psychol Med 1993; 23:709-18.
13. DeMartinis, NA; Schweizer, E; et al. An open-label trial of nefazodone in high comorbity panic disorder. J Clin Psychiatry 1996; 57:245-8.
14. Flament, MF; Bisserbe, JC: Pharmacologic treatment of obsessive-compulsive disorder: Comparative studies. J Clin Psychiatry 1997; 58 (suppl 12):18-22.
15. Gelernter, CS; Uhde, TW, Cimbolic, P, e al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991; 48:938-45.
16. Gentil, V.; Lotufo-Neto, F.; Andrade, L; Cordas, T.; Bernik, M.; Ramos, R.; Maciel, L.; Miyakawa, E.; Gorenstein, C. Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. Journal of Psychopharmacology 1993; 7:316-24.
17. Graef F. Role of 5HT in defensive behavior and anxiety. Ver Neurosci 1993; 4:181-211.
18. Greenberg, PE; Sissitsky, T; Kessler, FC; Finkelstein, SN; Berndt, ER; Davidson, JR. The economic burden of anxiety disorders in 1990s. J Clin Psychiatry 1999; 60:427-435.
19. Greist, JH; Jefferson, JW, Kobak, KA; et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A metaanalysis. Arch Gen Psychiatry 1995; 52:53-60.
20. Guidotti A, Baraldi, M; Leon, A, e cols., Benzodiazepines: A tool to explore the biochemical and neurophysiological basis of anxiety. Federation Proceedings 1990; 39:1039-42.
21. Heimberg, RG; Liebowitz, MR; Hope, DA, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: 12-Week outcome. Arch Gen Psychiatry 1998; 55:1133-41.
22. Katschnig, H; Amering, M; Stolk, JM, et al. Predictors of quality of life in a long-term follow-up study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull 1996; 32:149-55.
23. Kessler, RC; McGonagle, KA; Zhao, S; Nelson, CB; Hughes, M; Eshleman, S; Wittchen, H; Kendeler, KS - Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in United States. Arch Gen Psychiatry 1994; 51:8-19.
24. Klein, DF - Delination of two drug-responsive anxiety syndromes. Psychopharmacology 1964; 5:397-408.
25. Klein, DF - Importance of psychiatric diagnoses in prediction of clinical drug effects. Arch Gen Psychiatry 1967; 16:188-96.
26. Koran, LM; McElroy, SL; Davidson, JRT; et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996; 16:121-9.
27. Liebowitz, MR; Schneier, FR; Campeas, R; eta al. Phenelzine versus atenolol in social phobia: A placebo controlled comparison. Arch Gen Psychiatry 1992; 49:290-300.
28. Mavissakalian M, Perel, JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992; 149: 1053-7.
29. Modigh K, Westberg P, Eriksson, E. Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo-controlled trial. J Clin Psychopharmacol 1992; 12:251-61.
30. Myers, JK; Weissman, MM; Tischler, GL, et al. Six-month prevalence of psychiatris disorders in three communities 1980 to 1982. Arch Gen Psychiatry 1984; 41:949-58.
31. Nagy, LM; Krystal JH, Woods SW, et al. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5 Year naturalistic follow-up study. Arch Gen Psychiatry 1989; 46:993-9.
32. Papp LA, Sinha SS, Martinez JM, Coplan JD, Amchin J, Gorman JM. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 1998; 34(2):207-9.
33. Pollack, MH; Otto, MW; Rosenbaum, JF, et al: Longitudinal course of panic disorder: findings from Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry 1990; 51 (suppl A):12-6.
34. Ramussen, AS; Eisen, JL. Clinical and epidemiologic findings of significance to neuropharmacologic trials in OCD. Psychopharmacol Bull 1988; 24:466-70.
35. Rosenbaum, JF; Pollock, RA, Jordan, SK, etal. The pharmacotherapy of panic disorder. Bull Menninger Clin 1996; 60 (2 suppl A):A54-A75.
36. Schneier FR; Johnson J, Horing CD, et al. Social phobia: Comorbidity and morbidity in na epidemiclogic sample. Arch Gen Psychiatry 1992; 49:282-8.
37. Schneier FR, Goetz, D; Campeas, R; etal. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172:70-7.
38. Schweizer, E.; Rickels, K; Uhlenhuth, EH. Issues in the long-term treatment of anxiety disorders. In: Psychopharmacology: The Hourth Generation of Progress. Editado por: Bloom FE, Kupfer, DJ. New York, Raven, 1995; pp 1349-59.
39. Sheehan DV, Ballenger, JC; Jacobsen, G. Treatment of endogenous anxiety with phobic, hysterical and hypochondracal symptoms. Arch Gen Psychiatry 1980; 37:51-9.
40. Spiegel, DA. Efficacy studies of alprazolam in panic disorder. Psychopharmacol Bull 1998; 34:191-5.
41. Stein, MB; Chartier, MJ; Hazen AL; et al. Paroxetine in the treatment of generalized social phobia: Open label treatment and double-blind pacebo-controlled discontinuation. J Clin Psychopharmacol 1996; 16: 218-22.
42. Thomas RE. Benzodiazepine use and motor vehicle accidents: Systematic review of reported association. Can Fam Physician 1998; 44:799-808.
43. Van Ameringen, MA; Lane, RM; Walter, JR, et al. Sertraline treatment of generalized social phobia: A 20-week, double-bind, placebo-controlled study. Am J Psychiatry 2001; 158:275-81.
44. Versiani, M; Mundim, FD; Nardi, AE; et al. Tranylcypromine social phobia. J Clin Psychopharmacol 1988; 8:279-83.
45. Versiani, M; Nardi, AE; Mundim, FD; et al. Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161:353-60.
46. Weissman, MM; Bland, RC; Canino, GJ; et al. The cross national epidemiology of obsessive-compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 1994; 55(suppl):5-10.
47. Woodman, CL, Noyes, R. Panic disorder: Treatment with valproate. J Clin Psychiatry 1994; 55:134-6.